-
1
-
-
79151478658
-
Cancer survival in Australia Canada Denmark Norway Sweden and the UK 1995-2007 the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data
-
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011;377:127-38.
-
(2011)
Lancet
, vol.377
, pp. 127-138
-
-
Coleman, M.P.1
Forman, D.2
Bryant, H.3
Butler, J.4
Rachet, B.5
Maringe, C.6
-
2
-
-
33846613340
-
Modern chemotherapy management of recurrent ovarian cancer: A multicentre study
-
Chan S, Griffin M, Stewart J, Gregory K, Hughes A, Awwad S, et al. Modern chemotherapy management of recurrent ovarian cancer: a multicentre study. Clin Oncol (R Coll Radiol) 2007;19:129-34.
-
(2007)
Clin Oncol (R Coll Radiol
, vol.19
, pp. 129-134
-
-
Chan, S.1
Griffin, M.2
Stewart, J.3
Gregory, K.4
Hughes, A.5
Awwad, S.6
-
3
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
4
-
-
84857405773
-
Optimal assessment of response in ovarian cancer
-
Eisenhauer EA. Optimal assessment of response in ovarian cancer. Ann Oncol 2011;22 Suppl 8:viii49-viii51.
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 8
-
-
Eisenhauer, E.A.1
-
5
-
-
84886949653
-
Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer
-
Buckler AJ, Schwartz LH, Petrick N, McNitt-Gray M, Zhao B, Fenimore C, et al. Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer. Opt Express 2010;18:15267-82.
-
(2010)
Opt Express
, vol.18
, pp. 15267-15282
-
-
Buckler, A.J.1
Schwartz, L.H.2
Petrick, N.3
McNitt-Gray, M.4
Zhao, B.5
Fenimore, C.6
-
6
-
-
84878095934
-
The clinical viewpoint: Definitions, limitations of RECIST, practical considerations of measurement
-
Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res 2013;19:2629-36.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2629-2636
-
-
Villaruz, L.C.1
Socinski, M.A.2
-
7
-
-
33846651571
-
Lung cancer: Computerized quantification of tumor response-initial results
-
Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor response-initial results. Radiology 2006;241:892-8.
-
(2006)
Radiology
, vol.241
, pp. 892-898
-
-
Zhao, B.1
Schwartz, L.H.2
Moskowitz, C.S.3
Ginsberg, M.S.4
Rizvi, N.A.5
Kris, M.G.6
-
8
-
-
63449134205
-
Considerations for the use of imaging tools for phase II treatment trials in oncology
-
Shankar LK, Van den AA, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ. Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res 2009;15:1891-7.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 1891-1897
-
-
Shankar, L.K.1
Van Den, A.A.2
Yap, J.3
Benjamin, R.4
Scheutze, S.5
Fitzgerald, T.J.6
-
9
-
-
33745955010
-
Positron emission tomography as an imaging biomarker
-
Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-92.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3282-3292
-
-
Weber, W.A.1
-
10
-
-
66149139452
-
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
-
Wahl RL, Jacene H,Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
-
(2009)
J Nucl Med
, vol.50
, Issue.SUPPL. 1.
-
-
Wahl, R.L.1
Jacene, H.2
Kasamon, Y.3
Lodge, M.A.4
-
11
-
-
32944461277
-
Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer
-
Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7445-7453
-
-
Avril, N.1
Sassen, S.2
Schmalfeldt, B.3
Naehrig, J.4
Rutke, S.5
Weber, W.A.6
-
12
-
-
84860736175
-
Repeatability of 18F-FDG uptake measurements in tumors: A metaanalysis
-
de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, et al. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med 2012;53:701-8.
-
(2012)
J Nucl Med
, vol.53
, pp. 701-708
-
-
De Langen, A.J.1
Vincent, A.2
Velasquez, L.M.3
Van Tinteren, H.4
Boellaard, R.5
Shankar, L.K.6
-
13
-
-
84884704277
-
Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: A meta-Analysis
-
Mghanga FP, Lan X, Bakari KH, Li C, Zhang Y. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-Analysis. Clin Breast Cancer 2013;13: 271-9.
-
(2013)
Clin Breast Cancer
, vol.13
, pp. 271-279
-
-
Mghanga, F.P.1
Lan, X.2
Bakari, K.H.3
Li, C.4
Zhang, Y.5
-
14
-
-
84878278608
-
Staging and monitoring in the treatment of lymphomas
-
Dupas B, Augeul-Meunier K, Frampas E, Bodet-Milin C, Gastinne T, Le Gouill S. Staging and monitoring in the treatment of lymphomas. Diagn Interv Imaging 2013 S2211-5684(12)00404-4.
-
(2013)
Diagn Interv Imaging
, vol.5684
, Issue.12
, pp. 00404-00414
-
-
Dupas, B.1
Augeul-Meunier, K.2
Frampas, E.3
Bodet-Milin, C.4
Gastinne, T.5
Le Gouill, S.6
-
15
-
-
0036789344
-
Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET
-
Hoekstra CJ, Hoekstra OS, Stroobants SG, Vansteenkiste J, Nuyts J, Smit EF, et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002;43: 1304-9.
-
(2002)
J Nucl Med
, vol.43
, pp. 1304-1309
-
-
Hoekstra, C.J.1
Hoekstra, O.S.2
Stroobants, S.G.3
Vansteenkiste, J.4
Nuyts, J.5
Smit, E.F.6
-
16
-
-
0032716268
-
Reproducibility of metabolic measurements in malignant tumors using FDG PET
-
Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-7.
-
(1999)
J Nucl Med
, vol.40
, pp. 1771-1777
-
-
Weber, W.A.1
Ziegler, S.I.2
Thodtmann, R.3
Hanauske, A.R.4
Schwaiger, M.5
-
17
-
-
70349650689
-
Repeatability of 18F-FDG PET in a multicenter phase i study of patients with advanced gastrointestinal malignancies
-
Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS, Lammertsma AA, et al. Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 2009;50:1646-54.
-
(2009)
J Nucl Med
, vol.50
, pp. 1646-1654
-
-
Velasquez, L.M.1
Boellaard, R.2
Kollia, G.3
Hayes, W.4
Hoekstra, O.S.5
Lammertsma, A.A.6
-
18
-
-
84895075030
-
Test-retest variability of various quantitative measures to characterize tracer uptake and/or tracer uptake heterogeneity in metastasized liver for patients with colorectal carcinoma
-
van Velden FH, Nissen IA, Jongsma F, Velasquez LM, Hayes W, Lammertsma AA, et al. Test-retest variability of various quantitative measures to characterize tracer uptake and/or tracer uptake heterogeneity in metastasized liver for patients with colorectal carcinoma. Mol Imaging Biol 2014;16:13-18.
-
(2014)
Mol Imaging Biol
, vol.16
, pp. 13-18
-
-
Van Velden, F.H.1
Nissen, I.A.2
Jongsma, F.3
Velasquez, L.M.4
Hayes, W.5
Lammertsma, A.A.6
-
19
-
-
80052855899
-
Interleukin-6 as a therapeutic target in human ovarian cancer
-
Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17:6083-96.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6083-6096
-
-
Coward, J.1
Kulbe, H.2
Chakravarty, P.3
Leader, D.4
Vassileva, V.5
Leinster, D.A.6
-
20
-
-
84855466019
-
A phase 3 trial of bevacizumab in ovarian cancer
-
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.
-
(2011)
N Engl J Med
, vol.365
, pp. 2484-2496
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
Ledermann, J.A.4
Pujade-Lauraine, E.5
Kristensen, G.6
-
21
-
-
80053561888
-
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer
-
Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29: 3798-804.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3798-3804
-
-
Ledermann, J.A.1
Hackshaw, A.2
Kaye, S.3
Jayson, G.4
Gabra, H.5
McNeish, I.6
-
22
-
-
84873619713
-
Targeted anti-vascular therapies for ovarian cancer: Current evidence
-
Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013;108:250-8.
-
(2013)
Br J Cancer
, vol.108
, pp. 250-258
-
-
Hall, M.1
Gourley, C.2
McNeish, I.3
Ledermann, J.4
Gore, M.5
Jayson, G.6
-
23
-
-
84867034899
-
The changing landscape of therapeutic strategies for recurrent ovarian cancer
-
Baumann KH, Wagner U, du BA. The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol 2012;8: 1135-47.
-
(2012)
Future Oncol
, vol.8
, pp. 1135-1147
-
-
Baumann, K.H.1
Wagner, U.2
Du, B.A.3
-
24
-
-
34249085905
-
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
-
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1753-1759
-
-
Choi, H.1
Charnsangavej, C.2
Faria, S.C.3
Macapinlac, H.A.4
Burgess, M.A.5
Patel, S.R.6
-
25
-
-
77956672580
-
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development
-
Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 2010;16: 4647-53.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4647-4653
-
-
Zhao, B.1
Oxnard, G.R.2
Moskowitz, C.S.3
Kris, M.G.4
Pao, W.5
Guo, P.6
-
26
-
-
84874267110
-
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings
-
Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, et al. Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings. Clin Nucl Med 2013;38:175-82.
-
(2013)
Clin Nucl Med
, vol.38
, pp. 175-182
-
-
Kumar, V.1
Nath, K.2
Berman, C.G.3
Kim, J.4
Tanvetyanon, T.5
Chiappori, A.A.6
|